Issue: March 2017, Posted Date: 3/8/2017

Accelerating Development of Enabled Formulations for Poorly Soluble Drugs


Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. Often solubility issues are often only discovered when the drug is first administered in clinical trials. Quotient Clinical has developed an innovative approach to identify and overcome solubility challenges, which enables formulations to be designed, manufactured and clinically evaluated rapidly. Data from the early stages of the clinical evaluation can be fed back into the process, allowing formulations to be modified, manufactured and passed straight into the clinic again. This unique approach means that formulation issues can be detected, corrected and clinically validated more quickly. Click here to download/view the whitepaper.

Related Taxonomy
This record has been viewed 373 times.


Click here to see the showcases

March 21-23
New York, NY

PDA Annual Meeting
April 3-5
Anaheim, CA

RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

Pre-filled Syringes East Coast
April 26-27
Boston, MA

AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

BIO 2017
June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

November 12-17
San Diego, CA



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions